Fasudil fOr redUcing elopemeNt and Spatial Disorientation
Status:
Active, not recruiting
Trial end date:
2022-03-30
Target enrollment:
Participant gender:
Summary
Fasudil, a Rho kinase inhibitor, is believed to reduce wandering behaviors of elopement and
getting lost by improving spatial memory and navigation through improvements in hippocampal
blood flow. Fasudil is non-sedating.
The aim of the study is to assess the effectiveness of oral fasudil in reducing wandering
behaviors of elopement and/or getting lost in subjects with dementia. In addition, effects on
wandering behaviors of excess movement and pacing, cognition, memory, neuropsychiatric
symptomatology, caregiver/nursing staff burden, and the safety and tolerability of fasudil
treatment will be assessed.